{
    "clinical_study": {
        "@rank": "164953", 
        "arm_group": [
            {
                "arm_group_label": "Palliative Surgery Group", 
                "description": "Patients who present to clinic with soft tissue sarcoma with metastatic lung disease who opt to proceed with palliative surgical treatment"
            }, 
            {
                "arm_group_label": "Non-surgical Group", 
                "description": "Patients who present to clinic with soft tissue sarcoma with metastatic lung disease who opt not to pursue palliative surgery"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the role of palliative surgery in improving Quality\n      of Life  (QoL) and symptom control for patients who present with a Soft Tissue Sarcoma (STS)\n      and metastatic lung disease. Responses to clinical Edmonton Symptom Assessment System -\n      Sarcoma Modified ( ESAS-SM) questionnaire for patients who have undergone surgery for\n      resection of the primary tumour will be compared to those that are unable to have surgery.\n      Data collected from this questionnaire can highlight the benefits in patients' QoL who\n      receive palliative surgical resection, and whether these benefits surmount those who are not\n      treated with palliative surgery."
        }, 
        "brief_title": "Evaluating Quality of Life in Patients With Soft Tissue Sarcoma Presenting With Metastatic Lung Disease", 
        "condition": [
            "Soft Tissue Sarcoma", 
            "Metastatic Lung Disease"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Lung Diseases", 
                "Sarcoma"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with soft tissue sarcoma with at least one pulmonary metastasis\n\n          -  Metastatic lung disease must have been present at time of initial presentation\n\n        Exclusion Criteria:\n\n          -  All patients under 18 will be excluded\n\n          -  Patients who have been previously undergone surgical resection of the primary tumor"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients presenting with soft tissue sarcoma with metastatic lung disease"
            }
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 5, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02080897", 
            "org_study_id": "Pro00044852"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "non-surgical", 
            "palliative surgery"
        ], 
        "lastchanged_date": "April 21, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Durham", 
                    "country": "United States", 
                    "state": "North Carolina", 
                    "zip": "27710"
                }, 
                "name": "Duke University Health System"
            }, 
            "investigator": {
                "last_name": "William Eward, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "2", 
        "official_title": "Evaluating Quality of Life in Patients With Soft Tissue Sarcoma Presenting With Metastatic Lung Disease Using the ESAS-Sarcoma Modified Questionnaire", 
        "overall_contact": {
            "email": "cameron.howes@duke.edu", 
            "last_name": "Cameron R Howes", 
            "phone": "919-613-5747"
        }, 
        "overall_official": {
            "affiliation": "Duke University", 
            "last_name": "William Eward, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The Edmonton Symptom Assessment System - Sarcoma Modified ( ESAS-SM) questionnaire will be completed at baseline, 6 weeks and 3, 6, 12, 24, 36 and 60 months post presentation/surgical intervention.", 
            "measure": "Change in QoL score using patient-response questionnaire", 
            "safety_issue": "No", 
            "time_frame": "questionnaire will be obtained at initial presentation and at up to 7 additional visits (6 weeks, 3 months, 6 months, 12 months, 24 months, 36 months and 60 months after initial presentation or treatment)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02080897"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Duke University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Duke University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Observational Model: Case Control, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "April 2014"
    }
}